Core Viewpoint - Perfect Medical (01830) anticipates a decrease in shareholders' profit for the six months ending September 30, 2025, to approximately HKD 93 million to HKD 98 million, down from HKD 141 million for the same period ending September 30, 2024, primarily due to the ongoing overseas travel by Hong Kong residents and a generally cautious consumer sentiment in the operating locations, leading to weakened consumer spending [1] Summary by Relevant Categories Financial Performance - Expected shareholders' profit for the six months ending September 30, 2025, is projected to be around HKD 93 million to HKD 98 million [1] - This represents a significant decrease from HKD 141 million for the same period in 2024 [1] Market Conditions - The decline in profit is attributed to the continued overseas travel of Hong Kong residents [1] - There is a prevailing cautious consumer sentiment in the locations where the group operates, contributing to reduced consumer spending [1]

华检医疗(01931)发布公告，于2025年11月26日该公司斥资1.25万港元回购2000股，回购价格为每股6.25 港元。 ...

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 41.9 yuan on November 26, 2025, down 0.12% from the previous day [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main business revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year [3] - The third quarter alone saw a main business revenue of 842 million yuan, reflecting a 2.34% increase year-on-year [3] - The company reported a gross profit margin of 41.69% and a net profit margin of 26.91% [3] Market Position - Tongce Medical's total market capitalization is 18.741 billion yuan, ranking 8th in the medical services industry [3] - The company has a price-to-earnings ratio (P/E) of 27.37, significantly lower than the industry average of 366.11, ranking 3rd in the industry [3] - The return on equity (ROE) stands at 11.8%, placing it 5th in the industry [3] Fund Flow Analysis - On November 26, 2025, the net inflow of main funds was 9.8015 million yuan, accounting for 5.38% of the total transaction amount [1][2] - Retail investors experienced a net outflow of 11.9863 million yuan, representing 6.58% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net outflows from retail investors on several days [2] Analyst Ratings - In the last 90 days, 10 institutions have rated the stock, with 7 buy ratings and 3 hold ratings [4] - The average target price set by analysts over the past 90 days is 51.78 yuan [4]

Core Viewpoint - The company, XiMa Medical (03309), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 160,000 shares at a total cost of HKD 277,200 [1] - The buyback price per share ranges from HKD 1.72 to HKD 1.74 [1]

同时，集团持续投入在医疗AI垂类领域。作为阿里巴巴集团在医疗健康领域的旗舰平台，集团不断深 化在to B的医疗垂类领域的AI应用和工具的佈局，探索满足医疗行业及医生不断增长的AI需求，加速医 疗AI领域的深耕与突破，推动业务高质量发展。 阿里健康(00241)发布截至2025年9月30日止六个月的中期业绩，集团业务保持高质量稳健增长，总收入 为166.97亿元人民币，同比增长17.0%。净利润额为12.66亿元人民币，同比增长64.7%。净利润率由 5.4%增长至7.6%。调整后净利润额为13.56亿元人民币，同比增长38.7%。 报告期内，阿里健康自营业务抓住医疗健康品等类目的供给侧结构性优化的机遇，持续提升自营业务的 运营效率，业务收入达143.8亿元人民币，同比增长18.6%。同时集团持续深化药企合作，积极引入头部 品牌，拓展合作渠道，进一步提升用户心智。自营业务的年度活跃用户数与会员ARPU持续增长。 截至2025年9月30日，公司运营的天猫健康平台拥有年化活跃消费者(过往于十二个月内在天猫健康平台 实际购买过一次或以上商品的消费者)保持持续增长，天猫健康平台商品交易总额(GMV)在过去六个月 中实现 ...

Core Points - Beijing's Medical Insurance Bureau has announced the addition of 11 new designated medical institutions for medical insurance services, including the Tongzhou Liyuan Gonghe Community Health Service Center [1] - Seven medical institutions, including the Chaoyang District Jian Sheng Nursing Home Medical Room, will no longer provide medical insurance services due to inability to continue [1] - Two designated medical institutions, including Beijing Aerospace Hospital, are now eligible to offer "Internet+" medical insurance services [2] Group 1 - 11 new medical institutions have been added to the designated medical insurance provider list, which will offer standardized, high-quality, and convenient services to insured individuals [1] - Seven institutions have had their agreements terminated and will no longer bear medical insurance responsibilities, with costs incurred at these institutions not covered by the medical insurance fund [1] - Beijing Aerospace Hospital and Huairou District Traditional Chinese Medicine Hospital have signed supplementary agreements to provide "Internet+" medical insurance services [2] Group 2 - 35 designated medical institutions, including Xuanwu Traditional Chinese Medicine Hospital, have undergone information changes [2] - Beijing Changping Traditional Chinese Medicine Hospital has been issued a breach notice for violating medical insurance service agreements [2] - After rectification, Beijing Changping Qianai Clinic has met the conditions to be a designated medical insurance institution, and the yellow card warning has been lifted [2]

11月26日，ST中珠（600568）披露详式权益变动报告书，步步高投资实控人张源披露，在未来12个月内无增加或减少上市公司股份的具体计划，不谋求 上市公司控制权。据披露，张源已控制大千生态、利源股份两家A股上市公司，并持有港股上市公司巨星传奇6.07%的股份。 约两周前，吴世春控制的梅花投资刚以4.03亿元入股ST中珠，成为公司第二大股东。短期内，两大明星资本的接连入局，市场普遍期待这家长期无实控人 的公司将迎来转机。 11月26日，ST中珠再次收获涨停。 拟3000万元受让第一大股东股权 回溯来看，11月24日晚，ST中珠发布公告称，深商集团于前一日与苏州步步高投资发展有限公司（简称"步步高投资"）签署了《股权转让协议》，深商 集团拟以3000万元的价格将其持有的深圳市朗地科技发展有限公司（简称"朗地科技"）100%股权转让给步步高投资。 本次股权转让完成后，朗地科技控股股东将由深商集团变更为步步高投资。 作为知名的一级市场天使投资人，吴世春今年频频出手。除了入股ST中珠，他还通过司法拍卖和二级市场增持的方式成为ST路通第一大股东。 据查询，朗地科技目前持有ST中珠3.8亿股股份，占公司总股本的19.08 ...

证券之星消息，11月26日医疗服务板块较上一交易日上涨0.45%，兰卫医学领涨。当日上证指数报收于 3864.18，下跌0.15%。深证成指报收于12907.83，上涨1.02%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301060 | 兰卫医学 | 10.79 | 7.90% | 41.00万 | | 4.44亿 | | 688621 | 阳光诺和 | 68.55 | 7.63% | 7.88万 | | · 5.37亿 | | 600568 | ST中珠 | 2.70 | 5.06% | 85.39万 | | 2.30亿 | | 688222 | 成都先导 | 23.40 | 2.45% | 11.00万 | | 2.60亿 | | 688046 | 药康生物 | 17.10 | 2.03% | 1.90万 | | 3269.53万 | | 002821 | 凯莱英 | 92.74 | 2.02% | 5.34万 | | 4.97亿 | | ...

Group 1 - The article discusses tax incentives for high-tech enterprises in special economic zones and Shanghai Pudong New Area, including a two-year exemption from corporate income tax and a 50% reduction for the following three years [3][4] - From January 1, 2018, high-tech enterprises or technology-based SMEs can carry forward losses for up to 10 years, extending the previous limit of 5 years [3][4] - High-tech enterprises recognized by the authorities can enjoy a reduced corporate income tax rate of 15% on income sourced from abroad, with specific calculations for tax credits [4][6] Group 2 - The qualification for high-tech enterprises is valid for three years from the date of certification, and companies must reapply to maintain their status [7] - Upon obtaining high-tech enterprise status, companies can start enjoying tax benefits from the year of certification [7] - Companies must retain specific documentation to support their claims for tax benefits, including R&D expenses, sales revenue, and intellectual property materials [7]

Group 1 - The stock of Meili Tianyuan Medical Health (02373) fell over 11% during the trading session [1] - The cumulative decline for the month exceeds 30% [1] - As of the report, the stock price is down 7.28%, trading at HKD 22.42, with a transaction volume of HKD 57.48 million [1]